{"product_id":"global-helicobacter-pylori-diagnostics-market-size-study-forecast-by-technology-immunoassays-poc-molecular-diagnostics-by-end-user-hospitals-diagnostics-laboratories-clinics-and-regional-analysis-2023-2030","title":"Global Helicobacter Pylori Diagnostics Market Size study \u0026 Forecast, by Technology (Immunoassays, POC, Molecular Diagnostics), by End User (Hospitals, Diagnostics Laboratories, Clinics), and Regional Analysis, 2023-2030","description":"\u003cp\u003eGlobal Helicobacter Pylori Diagnostics Market Size study \u0026amp; Forecast, by Technology (Immunoassays, POC, Molecular Diagnostics), by End User (Hospitals, Diagnostics Laboratories, Clinics), and Regional Analysis, 2023-2030\u003cbr\u003e\nGlobal Helicobacter Pylori Diagnostics Market is valued at approximately USD 601.2 million in 2022 and is anticipated to grow with a healthy growth rate of more than 6% over the forecast period 2023-2030. The Helicobacter pylori diagnostics market refers to the segment focused on the utilization of diagnostic tests and devices specifically designed for the detection and identification of Helicobacter pylori (H. pylori) bacteria in patients. These diagnostics play a crucial role in identifying H. pylori infections, which are associated with various gastrointestinal disorders, including peptic ulcers, gastritis, and stomach cancer. The market encompasses a range of diagnostic methods such as serological tests, urea breath tests, stool antigen tests, and molecular diagnostics, which aid healthcare professionals in accurate and timely diagnosis, enabling appropriate treatment and management of H. pylori-related conditions. The Helicobacter pylori diagnostics market is being driven by factors such as the rising prevalence of the disease and rising awareness regarding H. pylori infections.\u003c\/p\u003e\n\n\u003cp\u003eThe Helicobacter Pylori Diagnostics is used in diagnosis bacterial infections. Some of the most common bacterial infections include Tuberculosis, Chlamydia, gonorrhea, as well as other sexually transmitted diseases (STDs). Additionally, bacterial infections like gastroenteritis (commonly known as stomach flu) and urinary tract infections (UTIs) are also prevalent. The infectious disease like tuberculosis is also driving the market, According to World Health Organization, estimated 10.6 million people (95% UI: 9.9–11 million) who fell ill with TB worldwide in 2021 is an increase of 4.5% from 10.1 million (95% UI: 9.5–10.7 million in 2020).  Thus, rising infectious diseases fueling the growth for Helicobacter Pylori Diagnostics market.   In addition to the rising gastrointestinal disorder and advancements in diagnostic technologies may create lucrative opportunities for the market. However, the stringent regulatory Norms by the government may hinder the growth of the market throughout the forecast period of 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Helicobacter Pylori Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East \u0026amp; Africa. North America dominated the market in 2022 owing to the well-established healthcare infrastructure. The region has a robust network of diagnostic laboratories, hospitals, and healthcare facilities that provide comprehensive diagnostic services, including H. pylori diagnostics. Asia Pacific is considered the fastest growing region during the forecasted period due to the increasing healthcare expenditure. As people become more conscious of their health and have greater access to medical services, the demand for diagnostic tests, including H. pylori diagnostics, has risen. This trend contributes to the growth of the market.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nBio-Rad Laboratories Inc.\u003cbr\u003e\nF. Hoffmann-La Roche Ltd.\u003cbr\u003e\nAlpha Laboratories Ltd.\u003cbr\u003e\nBiohit Healthcare Ltd.\u003cbr\u003e\nMeridian Bioscience Inc.\u003cbr\u003e\nQuest Diagnostics\u003cbr\u003e\nCoris BioConcept\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nBecton, Dickinson and Co.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\nIn May 2022, Biomerica, Inc. achieved the CE Mark for its hp+detect diagnostic test, designed to detect Helicobacter pylori bacteria. This significant milestone allows Biomerica to commence the marketing and sales of its hp+detect diagnostic test in the European Union (EU) and other international markets. The company proceed with registering the product in each country where it intends to sell, ensuring compliance with local regulations. This achievement positions Biomerica to address the diagnostic needs related to H. pylori infections in these regions, providing healthcare professionals with a reliable and efficient tool for detecting this bacterium.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Helicobacter Pylori Diagnostics Market Report Scope:\u003cbr\u003e\nHistorical Data – 2020 - 2021\u003cbr\u003e\nBase Year for Estimation – 2022\u003cbr\u003e\nForecast period - 2023-2030\u003cbr\u003e\nReport Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered – Technology, End User, Region\u003cbr\u003e\nRegional Scope - North America; Europe; Asia Pacific; Latin America; Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.\u003c\/p\u003e\n\n\u003cp\u003eThe detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Technology:\u003cbr\u003e\nImmunoassays\u003cbr\u003e\nPOC\u003cbr\u003e\nMolecular Diagnostics\u003c\/p\u003e\n\n\u003cp\u003eBy End User:\u003cbr\u003e\nHospitals\u003cbr\u003e\nDiagnostics Laboratories\u003cbr\u003e\nClinics\u003c\/p\u003e\n\n\n\u003cp\u003eBy Region:\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003cbr\u003e\nSaudi Arabia\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nRest of Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eCompanies \u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nBio-Rad Laboratories Inc.\u003cbr\u003e\nF. Hoffmann-La Roche Ltd.\u003cbr\u003e\nAlpha Laboratories Ltd.\u003cbr\u003e\nBiohit Healthcare Ltd.\u003cbr\u003e\nMeridian Bioscience Inc.\u003cbr\u003e\nQuest Diagnostics \u003cbr\u003e\nCoris BioConcept \u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nBecton, Dickinson and Co.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"July, 2023 \/ 200 Pages \/ MCW16237401","offer_id":47652458496306,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-helicobacter-pylori-diagnostics-market-size-study-forecast-by-technology-immunoassays-poc-molecular-diagnostics-by-end-user-hospitals-diagnostics-laboratories-clinics-and-regional-analysis-2023-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}